References

Ashley, A.A., K. Stepniewska, N. Lindegardh, R. McGready and R. Hutagalung et al., 2007. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop. Med. Int. Health, 12: 201-208.
Direct Link  |  

Borrmann, S., W.M. Sallas, S. Machevo, R. Gonzalez and A. Bjorkman et al., 2010. The effect of food on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablet (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop. Med. Int. Health, 15: 434-441.

Byakika-Kibwika, P., M. Lamorde, J. Mayito, L. Nabukeera and R. Namakula et al., 2010. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J. Antimicrob. Chemother., 67: 2213-2221.
CrossRef  |  

Cohen, C., A. Karstaedt, J. Frean, J. Thomas and N. Govender et al., 2005. Increased prevalence of severe malaria in HIV-infected adults in South Africa. Clin. Infectious Dis., 41: 1631-1637.
PubMed  |  

Djimde, A. and G. Lefevre, 2009. Understanding the pharmacokinetics of Coartem^®. Malar. J., 8: S4-S4.
CrossRef  |  

Dooley, K.E., C. Flexner and A.S. Andrade, 2008. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: Repercussions for resource-limited countries. J. Infectious Dis., 198: 948-961.
CrossRef  |  

Ezzet, F., M. van Vugt, F. Nosten, S. Looareesuwan and N.J. White, 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother., 44: 697-704.
CrossRef  |  

Ezzet, F., R. Mull and J. Karbwang, 1998. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patients. Br. J. Clin. Pharmacol., 46: 553-561.
CrossRef  |  

Flateau, C., G. Le Loup and G. Pialoux, 2011. Consequences of HIV infection on malaria and therapeutic implications: A systematic review. Lancet Infectious Dis., 11: 541-556.
CrossRef  |  

French, N., J. Nakiyingi, E. Lugada, C. Watera, J. Whitworth and C. Gilks, 2001. Increasing rates of malarial fever with deteriorating immune status in HIV 1 infected Ugandan adults. AIDS, 15: 899-906.
PubMed  |  Direct Link  |  

Huang, L., S. Parikh, P.J. Rosenthal, P. Lizak and F. Marzan et al., 2012. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J. Acquir. Immune Def. Syndr., 61: 310-316.

Idigbe, E.O., T.A. Adewole, G. Eisen, P. Kanki and N.N. Odunukwe et al., 2005. Management of HIV-1 infection with a combination of nevirapine, stavudine and lamivudine: a preliminary report on the Nigerian antiretroviral program. J. Acquir. Immune Defic. Syndr., 40: 65-69.
PubMed  |  

Kamya, M.R., A.F. Gasasira, J. Achan, T. Mebrahtu and T. Ruel et al., 2007. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bed nets on malaria among HIV-infected Ugandan children. AIDS, 21: 2059-2066.

Katabira, E. and M. Kamya, 2003. National Antiretroviral Treatment and Care Guidelines for Adults and Children. 1st Edn., Earnest Publishers, Kampala, Pages: 9.

Khoo, S., D. Back and P. Winstanely, 2005. The potential for interactions between antimalarials and antiretroviral drugs. AIDS, 19: 995-1005.
Direct Link  |  

Masters, P.A., T.A. O'Bryan, J. Zurlo, D.Q. Miller and N. Joshi, 2003. Trimethoprim-Sulfamethoxazole revisited. Arch. Int. Med., 163: 402-410.
CrossRef  |  

McGready, R., S.O. Tan, E.A. Ashley, M. Pimanpanarak and J. Viladpai-Nguen et al., 2008. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med., 5: e253-e253.
CrossRef  |  

Nakanjako, D., A.N. Kiragga, B. Castelnuovo, D.J. Kyabayinze and M.R. Kamya, 2011. Low prevalence of Plasmodium falciparum antigenaemia among asymptomatic HAART-treated adults in an urban cohort in Uganda. Malar. J., 10: 66-66.
CrossRef  |  

Piola, P., C. Fogg, F. Bajunirwe, S. Biraro and F. Grandesso et al., 2005. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: A randomised trial. Lancet, 365: 1467-1473.
PubMed  |  

Proietti, C., D.D. Pettinato, B.N. Kannoi, E. Ntege and A. Cristani et al., 2011. Continuing intense malaria transmission in northern Uganda. Am. J. Trop. Med. Hyg., 84: 830-837.
CrossRef  |  

Rasheed, A., S.M. Khan, M.Y. Awan, U. Khurshid and K. Ahmad, 2011. Efficacy and safety of artemether-lumefantrine in uncomplicated malaria in Liberia. J. Pak. Med. Assoc., 61: 131-134.

Tshefu, A.K., O. Gaye, K. Kayentao, R. Thompson and K.M. Bhatt et al., 2010. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: A randomised non-inferiority trial. Lancet, 375: 1457-1467.
CrossRef  |  

WHO, 2010. Guidelines for the Treatment of Malaria. 2nd Edn., World Health Organisation, Geneva, Switzerland.

WHO, UNAIDS and UNICEF, 2007. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector: Progress report. Geneva, Switzerland.

WHO/UNAIDS, 2000. Provisional WHO/UNAIDS/UNICEF secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Geneva: UNAIDS.

White, N.J., M. van Vugt and F. Ezzet, 1999. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinetics, 37: 105-125.

Whitworth, J., D. Morgan, M. Quigley, A. Smith and B. Mayanja et al., 2000. Effect of HIV-1 and increasing immunosuppresion on malaria parasitemia and clinical episodes in adults in rural Uganda: A cohort study. Lancet, 356: 1051-1056.

Zeng, M.Y., Z.L. Lu, S.C. Yeng, M. Zhang, J. Liao, S.L. Liu and X.H. Teng, 1996. Determination of benflumetol in human plasma by reversed phase high performance liquid chromatography. J. Chromatogr. B: Biomed. Sci. Appl., 2: 299-306.
PubMed  |